NXL

Nexalin Technology Inc. Common Stock (NXL)

Stock · NASDAQ · Health Care

$2.35as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 2, 2026

NXL Listed Among Stocks With Notable Price Movement. Nexalin Technology shares appeared in several daily market lists tracking top gainers and notable movers. The stock is currently flagged with a high beta signal, indicating it tends to move more sharply than the broader market. While specific company news was not provided, its inclusion in these lists highlights recent volatility in trading activity.

Active signals

Support level
$0.3062
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus

What NXL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike24-9.5%29%
Bollinger Band Breakdown14-7.9%21%
Bollinger Band Breakout12-26.4%25%
Any 20-session window (baseline)-13.7%33%

Computed by MarketWall from daily closing prices since July 5, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About NXL

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 heads…

Sector
Health Care
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Employees
8

Fundamentals

1-day range
$2.1$2.59
Market cap
$7.45M
P/E (trailing)
—
P/E (forward)
-0.32
EPS (trailing)
$-0.47
Dividend yield
—
Beta
4.19
Avg. volume
1.02M
52-week range
$2.38$50.7

How Nexalin Technology Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$301.6KSG&A$4.40M (1458%)R&D$1.08M (359%)Cost of Revenue$61.4K (20%)NXL

Source: 10-K filed Mar 25, 2026 · via SEC EDGAR / Finnhub

Gross Profit$240.3K(80%)
Operating Income-$8.39M(-2782%)

Forecasts

1 analyst ratings

Buy 80%
Hold 20%
Sell 0%
1-year price forecast
High
$15
+538.3%
Median
$15
+538.3%
Low
$15
+538.3%

Nexalin Technology Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • NXL
    Nexalin Technology Inc. Common Stock
    $2.35
    ▼ 4.08%
    Market cap $7.45MP/E —
    $2.38$50.7
  • NDRA
    ENDRA Life Sciences Inc. Common Stock
    $4.74
    ▼ 7.06%
    Market cap $5.68MP/E —
    $2.96$8
  • NUWE
    Nuwellis Inc. Common Stock
    $0.55
    ▲ 0.00%
    Market cap $5.26MP/E 0.03
    $0.4444$172.9
  • ITOC
    iTonic Holdings Ltd Class A Ordinary Shares
    $3.84
    ▼ 4.24%
    Market cap $4.94MP/E —
    $3.51$18.4
  • VBIO
    Valion Bio Inc. Common Stock
    $1.17
    ▼ 4.88%
    Market cap $1.14MP/E —
    $1.11$32.5
  • IRIX
    IRIDEX Corporation Common Stock
    $0.81
    ▼ 1.22%
    Market cap $14.61MP/E —
    $0.607$1.65
  • QTI
    QT Imaging Holdings Inc. Common Stock
    $2.4
    ▲ 0.84%
    Market cap $37.38MP/E —
    $2.38$19.05

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Institutional Ownership

March 31, 2026

Total shares held
1.00M
Total value held
$344.2K
Institutional holders
21
Top holders this quarter
  • Unknown384.5K
  • Unknown247.0K
  • Unknown126.5K
  • Unknown32.3K
  • Unknown24.1K
  • Unknown23.5K
  • Unknown23.3K
  • Unknown22.9K
  • Unknown22.2K
  • Unknown20.9K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.